转录因子激活蛋白-2a在老年肺腺癌病人中的表达情况及与临床病理参数的相关性

doi:10.3969/j.issn.1003-9198.2021.10.010

实用老年医学 ›› 2021, Vol. 35 ›› Issue (10): 1036-1039.doi: 10.3969/j.issn.1003-9198.2021.10.010

转录因子激活蛋白-2a在老年肺腺癌病人中的表达情况及与临床病理参数的相关性

方乐平, 董振, 樊卫飞

210024 江苏省南京市,南京医科大学附属老年医院血液肿瘤科(方乐平,樊卫飞);
222023 江苏省南京市,南京医科大学附属明基医院放疗科(董振)

收稿日期:2020-11-16 出版日期:2021-10-20 发布日期:2021-10-13
通讯作者: 樊卫飞,Email:fwfei1974@126.com
基金资助:
南京医科大学科技发展基金资助项目(NMUB2018181)

Expression of transcription factor activator protein-2a in elderly patients with lung adenocarcinoma and its relationship with clinicopathological parameters

FANG Le-ping, FAN Wei-fei, DONG Zhen

FANG Le-ping, FAN Wei-fei, Department of Hematology Oncology, Geriatric Hospital of Nanjing Medical University, Nanjing 210024, China;
DONG Zhen, Department of Radiotherapy, BenQ Medical Center Affiliated to Nanjing Medical University, Nanjing 222023, China

Received:2020-11-16 Online:2021-10-20 Published:2021-10-13

摘要/Abstract

摘要： 目的探讨转录因子激活蛋白-2a(TFAP-2a)在老年肺腺癌病人中的表达情况及与临床病理参数的相关性。方法通过生物信息学数据挖掘TFAP-2a在肺腺癌组织与正常肺组织中的表达差异及其对肺腺癌预后的影响;收集2015年8月至2020年3月切除的64份老年肺腺癌组织标本及25份老年正常肺组织标本,采用免疫组化染色法测定TFAP-2a的表达情况,分析老年肺腺癌组织中TFAP-2a的表达水平与临床病理参数的相关性。结果 GEPIA数据库分析结果显示,肺腺癌组织中TFAP-2a的表达量显著高于正常肺组织(P<0.05),但TFAP-2a的表达水平与肺腺癌的TNM分期无关(P>0.05)。KMplot数据库分析结果显示,TFAP-2a低表达的肺腺癌病人的无复发生存期和总生存期相较于高表达病人明显获益(均P<0.05)。免疫组化染色结果显示,老年肺腺癌组织TFAP-2a高表达的比例显著高于老年正常肺组织(P<0.01),并且在有淋巴结转移及中-低分化的老年肺腺癌病人中,TFAP-2a高表达的比例更高(P<0.05)。结论 TFAP-2a在老年肺腺癌病人中呈高表达,过表达TFAP-2a的老年肺腺癌分化更差,更易发生淋巴结转移。

关键词: 转录因子激活蛋白-2a, 肺腺癌, 预后, 生物信息学

Abstract: Objective To investigate the expression of transcription factor activator protein-2a (TFAP-2a) in the elderly patients with lung adenocarcinoma and its relationship with clinicopathological parameters. Methods The difference of TFAP-2a expression between lung adenocarcinoma and normal lung tissue and its effect on the prognosis of lung adenocarcinoma were analyzed by bioinformatics data. A total of 64 cases of elderly lung adenocarcinoma tissue and 25 cases of elderly normal lung tissue were collected from August 2015 to March 2020, and the expression of TFAP-2a was detected by immunohistochemical staining, and the correlation between TFAP-2a expression and clinicopathological parameters was analyzed. Results The GEPIA database analysis results showed that the expression level of TFAP-2a in lung adenocarcinoma tissue was significantly higher than that in normal lung tissue (P<0.05), but there were no significant differences among lung adenocarcinoma tissues with different TNM staging (P>0.05). KMplot database analysis results showed that the progression-free survival and overall survival of the patients with lung adenocarcinoma with low expression of TFAP-2a were better than those with high expression of TFAP-2a (all P<0.05). The immunohistochemical staining results showed that the proportion of high expression of TFAP-2a in the elderly lung adenocarcinoma tissue was significant higher than that in the elderly normal lung tissue (P<0.01), and the proportion of high expression of TFAP-2a in the elderly patients with lung adenocarcinoma who had lymph node metastasis and moderate-low differentiation was higher (P<0.05). Conclusions TFAP-2a is highly expressed in the elderly patients with lung adenocarcinoma. The lung adenocarcinoma with over expression of TFAP-2a is poorer in differentiation and more prone to lymph node metastasis.

Key words: transcription factor activator protein-2a, lung adenocarcinoma, prognosis, bioinformatics

中图分类号:

R 734.2

方乐平, 董振, 樊卫飞. 转录因子激活蛋白-2a在老年肺腺癌病人中的表达情况及与临床病理参数的相关性[J]. 实用老年医学, 2021, 35(10): 1036-1039.

FANG Le-ping, FAN Wei-fei, DONG Zhen. Expression of transcription factor activator protein-2a in elderly patients with lung adenocarcinoma and its relationship with clinicopathological parameters[J]. Practical Geriatrics, 2021, 35(10): 1036-1039.

参考文献

[1] OKAMOTO I, NOKIHARA H, NOMURA S, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6(5): e196828.
[2] LIU Y H, QIAN P D, ZHU W, et al. TFAP2A induced KRT16 as an oncogene in lung adenocarcinoma via EMT[J]. Int J Biol Sci, 2019, 15(7):1419-1428.
[3] KANG J, KIM W, LEE S, et al. TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation[J]. Oncogene, 2017, 36(11):1585-1596.
[4] ZHANG L L, LU J, LIU R Q, et al. Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells[J]. Acta Pharmacol Sin, 2020, 41(10):1357-1365.
[5] DO H, KIM D, KANG J, et al. TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells[J]. Biol Res, 2019, 52(1):35.
[6] FU L Y, SHI K, WANG J S, et al. TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling[J]. Mol Cancer, 2014, 13:89.
[7] ZHOU G R, FAN Z H, ZHU W, et al. TFAP2A induced ITPKA serves as an oncogene and interacts with DBN1 in lung adenocarcinoma[J]. Int J Biol Sci, 2020, 16(3):504-514.
[8] MENG X J, MENG C D, YANG B, et al. AP-2α downregulation by cigarette smoke condensate is counteracted by p53 in human lung cancer cells[J]. Int J Mol Med, 2014, 34(4):1094-1100.
[9] SUN X J, RITZENTHALER J D, ZHONG X R, et al. Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha[J]. Cancer Res, 2009, 69(16):6445-6453.
[10] CHEN J, LIU X B, XU Y C, et al. TFAP2C-activated MALAT1 modulates the chemoresistance of docetaxel-resistant lung adenocarcinoma cells[J]. Mol Ther Nucleic Acids, 2019, 14:567-582.
[11] ZHANG N S, LI Y K, XIE M Y, et al. DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma[J]. Biochem Pharmacol, 2020, 172:113772.

[1]	连芸, 蒋文, 朱方, 成语, 赵慧慧. 老年与年轻艾滋病相关淋巴瘤病人临床特点及预后分析[J]. 实用老年医学, 2024, 38(9): 920-925.
[2]	王新平, 谢柏梅, 卫国, 叶晓莉, 赵亚芸, 谭小田. 老年特发性间质性肺炎病人血清S100A9及sCD163表达水平及临床意义[J]. 实用老年医学, 2024, 38(8): 802-807.
[3]	薛冰艳, 徐瑞彤, 顾丹阳, 朱国琴. 81例老年胰腺神经内分泌肿瘤病人的临床病理特征与预后相关性分析[J]. 实用老年医学, 2024, 38(7): 718-721.
[4]	陈吐芬, 张波. 50例老年戊型肝炎临床特点与血清学特征分析[J]. 实用老年医学, 2024, 38(7): 722-726.
[5]	杨绍孔, 陈立文, 沈华, 张铮. 脓毒症心肌病诊断及预后标志物的研究进展[J]. 实用老年医学, 2024, 38(7): 748-752.
[6]	杜招娜, 姜文博, 牟俊宇, 俞成云, 夏伟. 经导管主动脉瓣置换术后新发持续完全性左束支传导阻滞的危险因素及短期预后分析[J]. 实用老年医学, 2024, 38(5): 500-437.
[7]	肖文, 胡秀, 李隽, 宋斌. 中性粒细胞/淋巴细胞比值与老年维持性血液透析病人预后的关系[J]. 实用老年医学, 2024, 38(4): 372-376.
[8]	胡芸, 汪曙红, 徐骥. 系统免疫炎症指数、白蛋白、甲胎蛋白与老年胃腺癌肝转移病人预后的相关性研究[J]. 实用老年医学, 2024, 38(4): 377-381.
[9]	王慧娟, 李霞. 主观认知下降转归为阿尔茨海默病的研究现状[J]. 实用老年医学, 2024, 38(4): 414-417.
[10]	彭泽通, 张尧, 刘斌. 贫血对老年社区获得性肺炎死亡的影响分析[J]. 实用老年医学, 2024, 38(3): 260-264.
[11]	陈璐, 姚俊英, 俞永贇, 范旻. MDT免疫营养支持治疗在老年颅脑手术病人中的应用效果[J]. 实用老年医学, 2024, 38(3): 278-282.
[12]	朱武刚, 翟晨彤, 刘德干, 徐文静. 外周血中性粒细胞与淋巴细胞比值对老年转移性食管癌免疫治疗预后的影响[J]. 实用老年医学, 2024, 38(2): 171-175.
[13]	李光耀, 叶碧华, 李小靓, 汤秦, 刘翠华. ApoB/ApoA1比值、甘油三酯-葡萄糖指数与老年创伤性脑损伤严重程度和预后的关系[J]. 实用老年医学, 2024, 38(10): 1049-1053.
[14]	张明, 陈曦, 刘跃洪, 谢德, 王志聪, 兰平文, 王光林. 红细胞体积分布宽度与老年髋部骨折病人预后的关系[J]. 实用老年医学, 2024, 38(1): 22-27.
[15]	孙洁, 查秀芳, 徐瑾, 赵君宁, 何伟, 张楠楠. 胃癌病人AHNAK表达与巨噬细胞浸润及预后的相关性[J]. 实用老年医学, 2024, 38(1): 49-53.

转录因子激活蛋白-2a在老年肺腺癌病人中的表达情况及与临床病理参数的相关性

Expression of transcription factor activator protein-2a in elderly patients with lung adenocarcinoma and its relationship with clinicopathological parameters

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10